Radiotherapy for stages I and IIA/B testicular seminoma

Area of Science:

• Oncology
• Radiation Oncology
• Clinical Trials

Background:

• Radiotherapy is a standard treatment for early-stage testicular seminoma, achieving high cure rates.
• Focus on minimizing treatment-related side effects is crucial due to excellent survival outcomes.
• Previous radiotherapy protocols involved larger treatment volumes and higher doses.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a modified radiotherapy approach for testicular seminoma.
• To assess outcomes using limited treatment portals and reduced irradiation doses.
• To establish a new standard of care for early-stage testicular seminoma.

Main Methods:

• Prospective multicenter trial involving 543 patients with clinical stage I, IIA, and IIB testicular seminoma.
• Stage I patients received 26 Gy to the para-aortic region.
• Stage IIA/B patients received 30/36 Gy to the para-aortic and high iliac lymph nodes.

Main Results:

• Relapse rates were 3.7% in stage I and 6.7% in stage IIA/B after a median follow-up of 55-55.5 months.
• Disease-specific survival was 99.6% for stage I and 100% for stage IIA/B.
• Acute toxicity was primarily moderate gastro-intestinal side effects, with no major late toxicity observed.

Conclusions:

• Limited volume para-aortic radiotherapy for stage I and para-aortic/high iliac irradiation for stage IIA/B is effective.
• This approach yields excellent cure rates with acceptable acute toxicity.
• The modified radiotherapy technique is recommended as a standard treatment for testicular seminoma.